Loading...
•
Mar 31, 2024
Merck Q1 2024 Earnings Report
Merck's financial performance for Q1 2024 showed strong growth across key therapeutic areas and strategic business development, with the launch of WINREVAIR in the U.S.
Key Takeaways
Merck reported a strong start to 2024, driven by innovation and a broad commercial portfolio. Key therapeutic areas experienced significant growth, and the company launched WINREVAIR in the U.S. The company is raising and narrowing its full-year outlook ranges for sales and non-GAAP EPS.
GAAP EPS was $1.87, including a $0.26 charge for the Harpoon Therapeutics acquisition.
Non-GAAP EPS was $2.07, also including the $0.26 charge for the Harpoon acquisition.
Merck received FDA approval for WINREVAIR for pulmonary arterial hypertension.
The company is initiating a Phase 3 trial for MK-1084 in combination with KEYTRUDA for metastatic NSCLC.
Merck
Merck
Merck Revenue by Segment
Revenue by Segment
Pharmaceutical Revenue
CapyFin.comAnimal Health Revenue
CapyFin.com Forward Guidance
Merck is raising and narrowing its full-year outlook ranges for sales and non-GAAP EPS.
Positive Outlook
- Full-year 2024 sales to be between $63.1 billion and $64.3 billion.
- Full-year non-GAAP EPS to be between $8.53 and $8.65.
- Strong global demand for oncology and vaccine products.
- Inflation-related price increases offset devaluation of Argentine peso.
- Non-GAAP effective income tax rate to be between 14.5% and 15.5%.
Challenges Ahead
- Includes a charge of $0.26 per share for the acquisition of Harpoon.
- Negative impact of foreign exchange of approximately 3% on sales.
- Negative impact of foreign exchange of approximately $0.30 per share on EPS.
- Outlook does not assume additional significant potential business development transactions.
- Devaluation of the Argentine peso.
Revenue & Expenses
Visualization of income flow from segment revenue to net income